Bristol-Myers Squibb Co.
Evaluating Complete Response/Remission Rate as a Surrogate Endpoint in Relapsed/Refractory Chronic Lymphocytic Leukemia
Researchers at Bristol-Myers Squibb Company and other institutions have identified complete response/remission (CR) rate as a potential surrogate endpoint in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The study, published in Leukemia Research, analyzed data from 20 randomized controlled trials (RCTs) involving